SIGNAL Trial

信号试验

• 批准号: nhmrc : GNT1042474
• 负责人: A/Pr Meg Jardine
• 金额: $ 268.16万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/signal-trial/1344405
• 关键词: SIGNAL; Trial

IgA nephropathy is one of the most common causes of kidney failure in Australia and around the world, but there are currently no specific treatments proven to prevent kidney failure. The SIGNAL trial, jointly led by Australian and Chinese researchers, will bring together leading experts from around the world to reliably ascertain the effects of steroid therapy in this condition, and could potentially prevent many people from developing kidney failure in the future.

伊加肾病是澳大利亚和世界各地肾衰竭最常见的原因之一，但目前还没有具体的治疗方法证明可以预防肾衰竭。SIGNAL试验由澳大利亚和中国的研究人员共同领导，将汇集来自世界各地的顶尖专家，以可靠地确定类固醇治疗在这种情况下的效果，并可能在未来预防许多人发生肾衰竭。